Annual report from the American Cancer Society says HIV is an underlying factor in a handful of cancer diagnoses.
In those with human immunodeficiency virus (HIV), there is a 10-fold higher cancer risk than in the general population, according to the annual Cancer Facts and Figures report from the American Cancer Society published today.
Cancer rates in HIV-positive individuals have decreased since the introduction of highly active antiretroviral therapy (HAART). Since HAART became available in 1996, there has been a 70% drop in Kaposi sarcoma and a 50% drop in non-Hodgkin lymphoma in those with HIV.
Because HIV compromises the immune system, it increases the risk of infections like human papillomavirus (HPV) that can lead to cervical cancer. Ten cancers are associated with HIV. These include non-Hodgkin lymphoma, cervical, liver, anal, and lung cancers.
LGBTQ+ (lesbian, gay, bisexual, transgender, and queer) individuals experience higher rates of HIV. For example, in 2019, 70% of HIV infections were attributed to male-to-male sexual contact.
The LGBTQ+ community experiences higher rates of health disparities overall. This is due to minority stress which the report defines as “the discrepancy and conflict that arises between the values of a historically minoritized group and the dominant culture or society.”
These stressors lead to higher rates of smoking, excess body weight, and alcohol consumption, which are all more prevalent in LBGTQ+ people than in heterosexuals. This can lead to lung cancer
Access to care is another barrier for the community. There are still nine states where it is legal for healthcare professionals to refuse to care for LGBTQ+ patients: Alabama, Arkansas, Florida, Illinois, Mississippi, Montana, Ohio, South Carolina, and Tennessee. The patients in these states account for an estimated 20% of the entire LGBTQ+ population.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
A Conversation with Jeremiah Johnson, Executive Director of PrEP4All
July 25th 2025Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the Lenacapavir breakthrough bandwagon.
Read More
Lenacapavir HIV PrEP: Not an AIDS Vaccine, but Vaccine Adjacent
June 19th 2025Experts and advocates say that twice-a-year HIV PrEP injections have the prevention potential of a vaccine — and that a once-a-year version of lenacapavir would be even better. But will Yeztugo be available to the people who would benefit most from HIV PrEP?
Read More